ARIA - Ariad Pharmaceuticals Inc. (NASDAQ Stock)

[greencat]

ARIA is in a nice position to make a higher high and will need to take out the high in April on this go around. I will be watching it with a lot of interest and may pull the trigger on it. It also looks good for a scalp..

Biotech is looking like it has heated up so these kind of plays may gain steam.

BUSINESS SUMMARY
ARIAD Pharmaceuticals, Inc., together with its subsidiaries, discovers and develops medicines to treat cancers by regulating cell signaling with small molecules in the United States and Europe. The company's cancer product candidate includes deforolimus, a potent protein mTOR inhibitor for the treatment of solid tumors, such as sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas. It offers Phase 3 clinical trial of oral deforolimus in patients with metastatic soft-tissue and bone sarcomas; and multiple clinical trials of deforolimus, including Phase 2 clinical trials in endometrial, breast, and prostate cancers. The company studies deforolimus as a single agent in multiple Phase 1 and Phase 2 clinical trials in patients with sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas. It conducts various multi-center Phase 1b trials of deforolimus in combination with anti-cancer therapies, which focuses on patients with various types of solid tumors; and Phase 1 trials of AP24534 that is used in the treatment of drug-resistant and refractory chronic myeloid leukemia, and hematological cancers. The company licenses NF-kB cell-signaling technology and treatment methods to pharmaceutical and biotechnology companies that conducts research to discover and develop drugs that modulate NF-kB cell-signaling and/or marketing such drugs; and ARGENT cell-signaling regulation technology for various pharmaceutical and biotechnology companies for research and development of therapeutic vaccines, and gene and cell therapy. It has a license agreement with Medinol, Ltd. to develop and commercialize deforolimus-eluting stents and other medical devices to prevent restenosis or reblockage of injured vessels; and collaboration agreement with Merck & Co., Inc. to develop deforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is based in Cambridge, Massachusetts.

Share Statistics
Average Volume (3 month)3: 556,627
Average Volume (10 day)3: 304,375
Shares Outstanding5: 69.48M
Float: 61.24M
% Held by Insiders1: 7.23%
% Held by Institutions1: 58.50%
Shares Short (as of 28-Jul-08)3: 8.57M
Short Ratio (as of 28-Jul-08)3: 17
Short % of Float (as of 28-Jul-08)3: 12.70%
Shares Short (prior month)3: 9.11M

Income Statement
Revenue (ttm): 6.15M
Revenue Per Share (ttm): 0.089
Qtrly Revenue Growth (yoy): 667.20%
Gross Profit (ttm): 3.58M
EBITDA (ttm): -60.76M
Net Income Avl to Common (ttm): -60.84M
Diluted EPS (ttm): -0.88
Qtrly Earnings Growth (yoy): N/A


Balance Sheet
Total Cash (mrq): 60.04M
Total Cash Per Share (mrq): 0.864
Total Debt (mrq): 13.82M
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 2.343
Book Value Per Share (mrq): -0.564


Cash Flow Statement
Operating Cash Flow (ttm): 28.64M
Levered Free Cash Flow (ttm): -37.19M

Major Holders Get Major Holders for:




BREAKDOWN

% of Shares Held by All Insider and 5% Owners: 7%
% of Shares Held by Institutional & Mutual Fund Owners: 59%
% of Float Held by Institutional & Mutual Fund Owners: 63%
Number of Institutions Holding Shares: 88
ARIA: Major Holders for ARIAD PHARM INC - Yahoo! Finance

[thegreatgate]

Up 15% P/M to $2.47 from $2.17 close

Earnings last Friday, 11/6:

Ariad's 3Q loss widens slightly on costs
Associated Press, 11.06.09, 08:07 AM EST

CAMBRIDGE, Mass. --

Drug developer Ariad Pharmaceuticals Inc. said Thursday its third-quarter loss widened slightly on overall costs as it continues developing potential cancer treatments.

The company reported a loss of $20.8 million, or 21 cents per share, compared with a loss of $20 million, or 29 cents per share, a year earlier. The company had fewer shares outstanding in the same period a year ago.

Revenue rose 40 percent, to $2.2 million from $1.5 million.

Analysts polled by Thomson Financial expected a loss of 18 cents per share on revenue of about $2.6 million.

The company's lead product candidates include the cancer treatment ridaforolimus, which is being developed in a partnership with Merck & Co.

Shares of Ariad closed at $1.98 Thursday.

[greencat]

ARIA has a triangle pattern. The last go around made a higher low. I expect to see a higher high.

ARIA Chart

[greencat]

ARIA is doing it to it. Looks ready again after a small pullback.

Originally Posted by greencat

ARIA has a triangle pattern. The last go around made a higher low. I expect to see a higher high.

ARIA Chart

[greencat]

Originally Posted by greencat

ARIA is doing it to it. Looks ready again after a small pullback.

ARIA gapped out of a channel like position and its also an upward channel if you look closely. Chart above is live and up to date.

[greencat]

ARIA generating a buy sugnal in my system. Made a highe low and should take out the old high.

ARIA Chart

[/QUOTE]

[greencat]

ARIA has made a nice move.

ARIA Chart

[greencat]

ARIA has filled the gap and broke a short term trendline. Looks like ARIA may be ready to resume the uptrend.

ARIA Chart

[greencat]

ARIA resuming the trend. I expect it to make a higher high.

Originally Posted by greencat

ARIA has filled the gap and broke a short term trendline. Looks like ARIA may be ready to resume the uptrend.

ARIA Chart